RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 64 filers reported holding RA PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $233,245,000 | +2.3% | 4,858,260 | 0.0% | 7.37% | +6.6% |
| Q4 2019 | $227,998,000 | +98.4% | 4,858,260 | 0.0% | 6.91% | +1.0% |
| Q3 2019 | $114,898,000 | -16.1% | 4,858,260 | 0.0% | 6.85% | -6.9% |
| Q2 2019 | $136,959,000 | +25.9% | 4,858,260 | 0.0% | 7.35% | +56.7% |
| Q1 2019 | $108,825,000 | +220.4% | 4,858,260 | 0.0% | 4.69% | +137.4% |
| Q4 2018 | $33,963,000 | -51.3% | 4,858,260 | +26.1% | 1.98% | -46.9% |
| Q3 2018 | $69,679,000 | +81.8% | 3,851,808 | 0.0% | 3.72% | +49.7% |
| Q2 2018 | $38,325,000 | +87.4% | 3,851,808 | 0.0% | 2.49% | +58.8% |
| Q1 2018 | $20,453,000 | +78.0% | 3,851,808 | +184.9% | 1.57% | +63.1% |
| Q4 2017 | $11,490,000 | -41.8% | 1,351,808 | 0.0% | 0.96% | -46.1% |
| Q3 2017 | $19,736,000 | -22.1% | 1,351,808 | 0.0% | 1.78% | -38.7% |
| Q2 2017 | $25,333,000 | -12.0% | 1,351,808 | 0.0% | 2.91% | -17.6% |
| Q1 2017 | $28,780,000 | +40.2% | 1,351,808 | 0.0% | 3.53% | +21.3% |
| Q4 2016 | $20,534,000 | – | 1,351,808 | – | 2.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |